Fatigue
Product Overview GLOW BLEND | 70mg (GHK-Cu 50mg, BPC-157 10mg, TB500 10mg) GLOW BLEND offers a multi-compound research reagent formulated strictly for in vitro and animal model studies
This is a life-threatening clinical-dermatological emergency that presents with a variety of symptoms and signs, including skin rash (especially of the exanthema type), which may be accompanied by fever, lymphadenomegaly, hepatitis, hematological (especially atypical lymphocytes and eosinophilia), renal, cardiac, pulmonary and pancreatic changes.1 The term DRESS was initially proposed by Bocquet et al., in 1996, in a review article on the drug hypersensitivity syndrome, which had been previously described under several different terms or synonymies, such as dapsone syndrome, anticonvulsant hypersensitivity syndrome, hydantoin syndrome, and allopurinol hypersensitivity syndrome, depending on the pharmacological agent involved, throughout the 20th century.2 The first case description compatible with DRESS was reported by Myers et al., in 1937
T cell mortality induced by the glucocorticoid and diterpene compound Kayadiol entails ferroptosis [87, 88]
